2 The technology
Description of the technology |
Elbasvir–grazoprevir (Zepatier, Merck Sharp & Dohme) is a fixed-dose combination drug. Elbasvir inhibits hepatitis C virus (HCV) non‑structural viral protein NS5A and grazoprevir inhibits HCV NS3/4A protease. |
Marketing authorisation |
Elbasvir–grazoprevir has a marketing authorisation in the UK for treating chronic hepatitis C in adults. The recommendations in the marketing authorisation for the specific genotypes are listed below:
|
Adverse reactions |
The summary of product characteristics includes headache and fatigue as very common adverse reactions, and nausea as a common reaction. For full details of adverse reactions and contraindications, see the summary of product characteristics. |
Recommended dose and schedule |
It is taken orally. The recommended dose of elbasvir–grazoprevir is 1 tablet once daily. Each tablet contains 50 mg elbasvir and 100 mg grazoprevir. |
Price |
Elbasvir–grazoprevir costs £12,166.67 per 28‑day pack. The total cost of a 12‑week treatment course is £36,500. The company has agreed a nationally available price reduction for elbasvir–grazoprevir with the Commercial Medicines Unit. The contract prices agreed through the framework are commercial in confidence. |